Anti–interleukin‐6 autoantibodies in rheumatic diseases

Hiroyuki Takemura, Hiroshi Suzuki*, Kazuyuki Yoshizaki, Atsushi Ogata, Takamichi Yuhara, Takao Akama, Kazuhide Yamane, Heihachiro Kashiwagi

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

58 Citations (Scopus)


Objective. To investigate the presence and the roles of anti–interleukin‐6 (anti–IL‐6) autoantibodies in rheumatic diseases, and to further elucidate clinical and pathophysiologic significance of anticytokine autoantibodies. Methods. Anti–IL‐6 IgG autoantibodies were measured by the 125I–IL‐6 binding activity of IgG, which was isolated from serum by protein A–Sepharose. Results. Nine of 52 sera (17.3%) from patients with systemic sclerosis (SSc) contained anti–IL‐6 antibodies, whereas only 1.9% of sera from normal subjects and 0–5% of sera from patients with other rheumatic diseases were positive for the antibodies. Moreover, anti–IL‐6 autoantibodies were found predominantly among patients with the limited form of SSc (42.9%), compared with those with the diffuse form (7.9%). Conclusion. Anti–IL‐6 IgG autoantibodies were detected in patients with SSc, particularly those with the limited form of the disease, at a significantly increased frequency compared with normal subjects and patients with other rheumatic diseases. These results suggest that the development of anti–IL‐6 autoantibodies and IL‐6 may have a role in the pathophysiology of SSc.

Original languageEnglish
Pages (from-to)940-943
Number of pages4
JournalArthritis & Rheumatism
Issue number8
Publication statusPublished - 1992 Aug
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)


Dive into the research topics of 'Anti–interleukin‐6 autoantibodies in rheumatic diseases'. Together they form a unique fingerprint.

Cite this